EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase III)

Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe COVID ‐19 in SARS ‐ CoV ‐2‐Infected Non‐Hospitalized Adults With Inhaled siRNA ‐Based MIR 19

M Khaitov iD, A Nikonova, V Smirnov, I Shilovsky, I Kofiadi, E Ruzanova, V Teplykh, D Makarov, A Vertichikh, S Teplykh, D Alpenidze, E Muldagalieva und 11 weitere

Allergy · 2025-07 · 80 (7) · 2031-2042

DOI: 10.1111/all.16515 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 03.03.2025. Verfasst von M Khaitov und 22 weiteren Autor:innen. Beteiligte Einrichtung: National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, RNA, Small Interfering, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID‐19 continues to be a major global health challenge. Inhaled siRNA‐based MIR 19 has been shown to reduce the time to clinical improvement in patients hospitalized with moderate COVID‐19.

Methods

We conducted an open‐label, randomized, controlled multicenter phase 2b‐3 trial (NCT05783206) evaluating the safety and efficacy of inhaled siR‐7‐EM/KK‐46 (MIR 19) (5.55 mg/day) in comparison with standard care (control group) in outpatients with mild COVID‐19 ( N = 492 for each group). The primary endpoint was the proportion of patients who developed moderate or severe COVID‐19 by the 28th day of randomization.

Results

Moderate or severe course of the disease was detected in 14 (2.85%) and 34 (6.91%) patients in the siR‐7‐EM/KK‐46 (5.55 mg) and standard therapy groups, respectively (the difference in proportions was −4.107% [95% CI: −7.28% to −1.03%] ( p = 0.002)). Adverse events (AE) were reported in 77 (15.65%) patients from the siR‐7‐EM/KK‐46 (5.55 mg) group, while in the standard therapy group AEs were registered in 100 (20.33%) patients. No severe, treatment‐related AEs were observed in the siR‐7‐EM/KK‐46 group. Conclusions siR‐7‐EM/KK‐46, a SARS‐CoV‐2‐specific RNAi‐based drug, was well‐tolerated and significantly decreased the progression to moderate/severe disease in outpatients with mild COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2RNA, Small InterferingMicroRNAsHumansMaleFemaleMiddle AgedAdultDisease ProgressionAdministration, InhalationAgedSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2clinical trialefficacysafetysiRNA

Substanzen

RNA, Small InterferingMicroRNAs

Autor:innen und Institutionen

  • National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.
  • Pirogov Russian National Research Medical University, Moscow, Russia.
  • I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Federal State Unitary Enterprise "the Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations" of Federal Medical and Biologic Agency (FSUE S…
  • Limited Liability Company 'Professorskaya Clinic', Perm, Russia.
  • St. Petersburg State Budgetary Healthcare Institution "City Clinic No. 117", St. Petersburg, Russia.

ORCID-Profile: M Khaitov, R Valenta

Zitieren

APA

Khaitov, M., Nikonova, A., Smirnov, V., Shilovsky, I., Kofiadi, I., Ruzanova, E., Teplykh, V., Makarov, D., Vertichikh, A., Teplykh, S., Alpenidze, D., Muldagalieva, E., Simakina, E., Ivanushkina, T., Zakharov, K., Melnikova, L., Medvedev, D., Zuev, O., Kudlay, D., …, & Skvortsova, V. (2025). Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe COVID ‐19 in SARS ‐ CoV ‐2‐Infected Non‐Hospitalized Adults With Inhaled siRNA ‐Based MIR 19. Allergy, 80(7), 2031-2042. https://doi.org/10.1111/all.16515

Vancouver

Khaitov M, Nikonova A, Smirnov V, Shilovsky I, Kofiadi I, Ruzanova E, et al. Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe COVID ‐19 in SARS ‐ CoV ‐2‐Infected Non‐Hospitalized Adults With Inhaled siRNA ‐Based MIR 19. Allergy. 2025;80(7):2031-2042. doi:10.1111/all.16515

BibTeX
@article{Khaitov2025,
  author = {Khaitov, M and Nikonova, A and Smirnov, V and Shilovsky, I and Kofiadi, I and Ruzanova, E and Teplykh, V and Makarov, D and Vertichikh, A and Teplykh, S and Alpenidze, D and Muldagalieva, E and Simakina, E and Ivanushkina, T and Zakharov, K and Melnikova, L and Medvedev, D and Zuev, O and Kudlay, D and Kruchko, D and Berzin, I and Valenta, R and Skvortsova, V},
  title = {Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe COVID ‐19 in SARS ‐ CoV ‐2‐Infected Non‐Hospitalized Adults With Inhaled siRNA ‐Based MIR 19},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {7},
  pages = {2031--2042},
  doi = {10.1111/all.16515}
}
Kostenlos starten →